Abstracts

293 – Identification of the First HIV-1 p24 Peptide for the Amerindian HLA-B*39:02 Allele

Background HIV evolution is driven by immunogenetic factors, particularly HLA alleles. Our group previously demonstrated that HLA-B*39:02, a prevalent allele in Amerindian populations, has been associated with better HIV outcomes in Mexico and selected polymorphisms within p24-Gag; however, the HIV-specific responses restricted by this allele remain undefined. In this study, we characterized an HLA-B*39:02–restricted p24…

839 – Very Early ART +/- VRC01 for In Utero HIV-1: Virologic Outcomes at 2 Years of Age in IMPAACT P1115

Background Neonatal ART has enabled virologic control and remission in children with in utero HIV-1. We report viral suppression outcomes through 2 years of age in neonates treated with ART with or without VRC01 and the prospect for treatment interruption to assess remission. Methods In the ongoing non-randomized, open-label IMPAACT P1115 study, infants ≥36 weeks (wks)…

873 – Primary Findings of IMPAACT 2016: A RCT of a Youth-Led Mental Health Intervention for Youth With HIV

Background Symptoms of depression, anxiety, and post-traumatic stress can negatively impact HIV outcomes and quality of life. Despite increased risk of mental distress among youth with HIV (YWH), mental health (MH) resources are limited in many countries. IMPAACT 2016 evaluated whether a group-based, peer-led, manualized Trauma Informed-Cognitive Behavioral Therapy (TI-CBT) intervention can improve MH symptoms…

614 – Pharmacist-Led Navigation Hepatitis C Linkage to Care Pilot Program in the Emergency Department

Background Hepatitis C virus (HCV) remains one of the most prevalent bloodborne infections in the United States. Despite the availability of curative direct-acting antiviral (DAA) treatments, infection rates are persistently high due to barriers to care, including difficulties in access and linkage to treatment. In response to the 2020 Centers for Disease Control and Prevention…

1076 – Effect of Machine-Learning-Guided Previsit Outreach to Patients at High Risk to Miss HIV Visits

Background Lifelong HIV care requires consistent clinic engagement. Identifying patients at higher risk of missing appointments, and providing timely reminders and support before scheduled visits, may improve attendance and clinical outcomes. Addressing this need is an important gap.  Methods We developed and cross-validated a machine-learning (ML)-based prediction model that uses longitudinal patient- and clinic-level features…

350 – 3D Chromatin Capture of the HIV Provirus Reveals Epigenetic Regulators of HIV Latency

Background Following acute HIV infection, proviral DNA integrates into the genome and becomes latent. However, while the epigenetic mechanisms silencing proviral DNA likely present druggable targets for a cure, they remain poorly understood. The integrated HIV provirus interacts with host chromatin at distant sites. Therefore, we hypothesized that a 3D examination of these sites in…

634 – HERV-K env Upregulation in Lymphoma Cells Under Antiretroviral-Chemotherapeutic Exposure

Background Endogenous retroviruses (ERVs) have a potential regulatory and pathogenic role in cancer. Antiretrovirals have been reported to influence HERV activity, but little is known about their interactions with classical chemotherapeutics. We investigated whether antiretrovirals Dolutegravir (DTG) and Doravirine (DOR) alter HERV-K expression and cytotoxic responses to Doxorubicin (D) and Vincristine (V) in lymphoma cell…

925 – Application of Claims-Based Frailty Index on Mortality Risk in a Cohort of Adults With HIV

Background Frailty, a measure of health vulnerability, is a determinant of health outcomes among people with HIV (PWH), including mortality. Claims-based frailty indices (CFI) enable scalable assessment using electronic health records when performance-based assessments are unavailable. We adapted and applied a CFI to quantify frailty burden and its distribution in an adult HIV population. Methods…